India Supreme Court Panel Delays Ruling On Novartis Glivec Appeal
This article was originally published in PharmAsia News
Executive Summary
India's two-judge panel of the Supreme Court delayed issuing a decision on an appeal by Novartis of the government's denial of a patent for its Glivec (imatinib) blood-cancer drug.